BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35508345)

  • 1. Acceptability of extending HPV-based cervical screening intervals from 3 to 5 years: an interview study with women in England.
    Nemec M; Waller J; Barnes J; Marlow LAV
    BMJ Open; 2022 May; 12(5):e058635. PubMed ID: 35508345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing key messages about extending cervical screening intervals.
    A V Marlow L; Nemec M; Barnes J; Waller J
    Patient Educ Couns; 2022 Aug; 105(8):2757-2762. PubMed ID: 35440375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maximising the acceptability of extended time intervals between screens in the NHS Cervical Screening Programme: An online experimental study.
    Hill E; Nemec M; Marlow L; Sherman SM; Waller J
    J Med Screen; 2021 Sep; 28(3):333-340. PubMed ID: 33175638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Women's acceptability of and experience with primary human papillomavirus testing for cervix screening: HPV FOCAL trial cross-sectional online survey results.
    Smith LW; Racey CS; Gondara L; Krajden M; Lee M; Martin RE; Stuart G; Peacock S; Coldman AJ; Franco EL; van Niekerk D; Ogilvie GS
    BMJ Open; 2021 Oct; 11(10):e052084. PubMed ID: 34620663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.
    Rebolj M; Cuschieri K; Mathews CS; Pesola F; Denton K; Kitchener H;
    BMJ; 2022 May; 377():e068776. PubMed ID: 35640960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Information needs among women taking part in primary HPV screening in England: a content analysis.
    Marlow L; Forster AS; McBride E; Rockliffe L; Kitchener H; Waller J
    BMJ Open; 2020 Dec; 10(12):e044630. PubMed ID: 33323451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Women's experiences of the renewed National Cervical Screening Program in Australia 12 months following implementation: a qualitative study.
    Dodd RH; Mac OA; McCaffery KJ
    BMJ Open; 2020 Jul; 10(7):e039041. PubMed ID: 32665351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical Cancer (HPV FOCAL) trial.
    Gottschlich A; Gondara L; Smith LW; Cook D; Martin RE; Lee M; Peacock S; Proctor L; Stuart G; Krajden M; Franco EL; van Niekerk D; Ogilvie G
    Int J Cancer; 2022 Sep; 151(6):897-905. PubMed ID: 35460070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychological Impact of Primary Screening (PIPS) for HPV: a protocol for a cross-sectional evaluation within the NHS cervical screening programme.
    McBride E; Marlow L; Forster AS; Moss S; Myles J; Kitchener H; Patnick J; Waller J
    BMJ Open; 2016 Dec; 6(12):e014356. PubMed ID: 28011816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the Acceptability and Uptake of HPV Self-Sampling Amongst Women Under- or Never-Screened for Cervical Cancer in Toronto (Ontario, Canada): An Intervention Study Protocol.
    Lofters A; Devotta K; Prakash V; Vahabi M
    Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Women's attitudes towards a human papillomavirus-based cervical cancer screening strategy: a systematic review.
    Nothacker J; Nury E; Roebl Mathieu M; Raatz H; Meerpohl JJ; Schmucker C
    BMJ Sex Reprod Health; 2022 Oct; 48(4):295-306. PubMed ID: 36223918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "A lot can happen in five years": Women's attitudes to extending cervical screening intervals.
    Kola-Palmer S; Rogers M; Halliday A; Rickford R
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13655. PubMed ID: 35838304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program.
    Smith LW; Khurshed F; van Niekerk DJ; Krajden M; Greene SB; Hobbs S; Coldman AJ; Franco EL; Ogilvie GS
    BMC Public Health; 2014 Oct; 14():1060. PubMed ID: 25303975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethnographic study of the barriers and facilitators to implementing human papillomavirus (HPV) self-sampling as a primary screening strategy for cervical cancer among Inuit women of Nunavik, Northern Quebec.
    Gamelin R; Hébert M; Tratt E; Brassard P
    Int J Circumpolar Health; 2022 Dec; 81(1):2032930. PubMed ID: 35166191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary HPV DNA based cervical cancer screening at 25 years: Views of young Australian women aged 16-28 years.
    Jayasinghe Y; Rangiah C; Gorelik A; Ogilvie G; Wark JD; Hartley S; Garland SM
    J Clin Virol; 2016 Mar; 76 Suppl 1():S74-S80. PubMed ID: 26589584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
    Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
    BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with human papillomavirus (HPV) test acceptability in primary screening for cervical cancer: A mixed methods research synthesis.
    Tatar O; Thompson E; Naz A; Perez S; Shapiro GK; Wade K; Zimet G; Gilca V; Janda M; Kahn J; Daley E; Rosberger Z
    Prev Med; 2018 Nov; 116():40-50. PubMed ID: 30172799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.